Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma
Introduction: Atezolizumab and bevacizumab (Ate/Bev) combination has become the new first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). Although several studies reported thyroid dysfunction after treatment with immune checkpoint inhibitors, the clinical and immunological sig...
Збережено в:
| Автори: | , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Karger Publishers
2023-05-01
|
| Серія: | Liver Cancer |
| Предмети: | |
| Онлайн доступ: | https://beta.karger.com/Article/FullText/531182 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|